Cargando…

Comparison of the efficacy and safety of rivaroxaban and low-molecular-weight heparin in Chinese lung cancer patients with nonhigh-risk pulmonary embolism

BACKGROUND: Data that guide selection of differing anticoagulant regimens for specific cancer-associated venous thromboembolism (VTE) are lacking. We aimed to compare the efficacy and safety of rivaroxaban and low-molecular-weight heparin (LMWH) against nonhigh-risk pulmonary embolism (PE) in Chines...

Descripción completa

Detalles Bibliográficos
Autores principales:	Song, Yijun, Yang, Dawei, Hou, Dongni, She, Jun, Song, Yuanlin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9893535/ https://www.ncbi.nlm.nih.gov/pubmed/36732741 http://dx.doi.org/10.1186/s12959-023-00453-y

Ejemplares similares

Saddle embolism is associated with the major adverse events in patients with nonhigh-risk pulmonary embolism
por: Kim, H, et al.
Publicado: (2012)

Efficacy of rivaroxaban for pulmonary embolism
por: Jia, Juan, et al.
Publicado: (2019)

Rivaroxaban for the Treatment of Pulmonary Embolism
por: Vanassche, Thomas, et al.
Publicado: (2013)

Efficacy of rivaroxaban for the treatment of Chinese patients with acute pulmonary embolism: A retrospective study
por: Wang, Lei, et al.
Publicado: (2021)

Heparin/rivaroxaban: Lack of efficacy: case report
Publicado: (2022)

Change in nonhigh-density lipoprotein cholesterol levels in adults with prediabetes
por: Liu, Jun-Ru, et al.
Publicado: (2017)

Effectiveness and Safety of Rivaroxaban and Low Molecular Weight Heparin in Cancer-Associated Venous Thromboembolism
por: Coleman, Craig I., et al.
Publicado: (2023)

Rivaroxaban treatment for young patients with pulmonary embolism (Review)
por: Wu, Haidi, et al.
Publicado: (2020)

Efficacy and Safety of Rivaroxaban versus Warfarin for the Treatment of Acute Pulmonary Embolism: A Real-World Study
por: Huang, Yan, et al.
Publicado: (2020)

Current status of rivaroxaban in elderly patients with pulmonary embolism (Review)
por: Song, Zi-Kai, et al.
Publicado: (2020)

High or Nonhigh Doses of Proton Pump Inhibitors for Patients with Peptic Ulcer Bleeding?
por: Hsieh, Yu-Hsi, et al.
Publicado: (2013)

Sequential Therapy of Nadroparin and Rivaroxaban in the Initial Treatment of Patients With Acute Pulmonary Embolism
por: Xiong, Wei, et al.
Publicado: (2022)

Corticosteroids: A Controversial Therapy for Coronavirus Disease 2019
por: She, Jun, et al.
Publicado: (2020)

Rivaroxaban versus Low-Molecular-Weight Heparin for Venous Thromboembolism in Gastrointestinal and Pancreatobiliary Cancer
por: Lee, Jang Ho, et al.
Publicado: (2019)

The Use of Rivaroxaban for Unprovoked Pulmonary Embolism in the Setting of Antithrombin Deficiency
por: Gryn, Oscar J, et al.
Publicado: (2020)

Monitoring of Anticoagulant Activity of Dabigatran and Rivaroxaban in the Presence of Heparins
por: Jakimczuk, Aleksandra, et al.
Publicado: (2022)

Challenges of vaccination and herd immunity in COVID‐19 and management strategies
por: She, Jun, et al.
Publicado: (2022)

Effect of Rivaroxaban on Fibrinolytic Therapy in Massive Pulmonary Embolism: Two Cases
por: Kim, Hye-Jin, et al.
Publicado: (2014)

Massive Spontaneous Haemothorax after Rivaroxaban Therapy for Acute Pulmonary Embolism
por: Yan, Denise Tan, et al.
Publicado: (2019)

Efficacy of low-dose rivaroxaban in an 88-year-old female with pulmonary embolism: A case report
por: Zhou, Huanyu, et al.
Publicado: (2019)

Direct oral anticoagulants vs. low-molecular-weight heparin for pulmonary embolism in patients with glioblastoma
por: Dubinski, Daniel, et al.
Publicado: (2021)

Pulmonary embolism in patients with COVID-19 and its treatment based on low-molecular-weight heparin
por: Hosseini, Amin, et al.
Publicado: (2020)

Apixaban/heparin/rivaroxaban: Melaena and thrombocytopenia: 2 case reports
Publicado: (2020)

Safety and Efficacy Evaluation of Antithrombotic Therapy with Rivaroxaban and Clopidogrel After PCI in Chinese Patients
por: Bai, Long, et al.
Publicado: (2022)

The efficacy and safety of low-molecular-weight heparin and unfractionated heparin in the treatment of cerebral venous sinus thrombosis
por: Afshari, Daryoush, et al.
Publicado: (2015)

Rivaroxaban Monotherapy in Patients with Pulmonary Embolism: Off-Label vs. Labeled Therapy
por: Di Micco, Pierpaolo, et al.
Publicado: (2022)

Can rivaroxaban be a drug of choice for treating heparin-induced thrombocytopenia in a patient with pulmonary thromboembolism?
por: Vavlukis, Marija, et al.
Publicado: (2017)

Efficacy and Safety Assessment of Rivaroxaban for the Treatment of Cerebral Venous Sinus Thrombosis in a Chinese Population
por: Jiang, Yi-ying, et al.
Publicado: (2022)

The Pharmacology, Efficacy, and Safety of Rivaroxaban in Obese Patient Populations
por: Ashton, Veronica, et al.
Publicado: (2020)

Comparison of glaucoma diagnostic accuracy of macular ganglion cell complex thickness based on nonhighly myopic and highly myopic normative database
por: Chen, Henry Shen-Lih, et al.
Publicado: (2016)

Pulmonary embolism and deep vein thrombosis in eosinophilic granulomatosis with polyangiitis successfully treated with rivaroxaban
por: Naito, Tomoyuki, et al.
Publicado: (2018)

Late Pulmonary Embolism after COVID-19 Pneumonia despite Adequate Rivaroxaban Treatment
por: Di Tano, Giuseppe, et al.
Publicado: (2020)

Chromogenic anti-FXa assay calibrated with low molecular weight heparin in patients treated with rivaroxaban and apixaban: possibilities and limitations
por: Margetić, Sandra, et al.
Publicado: (2019)

The anticoagulants rivaroxaban and low molecular weight heparin prevent PICC-related upper extremity venous thrombosis in cancer patients
por: Lv, Shoutian, et al.
Publicado: (2019)

Massive Fatal Pulmonary Embolism While on Therapeutic Heparin Drip
por: Hajouli, Said
Publicado: (2020)

Use of Prestudy Heparin Did Not Influence the Efficacy and Safety of Rivaroxaban in Patients Treated for Symptomatic Venous Thromboem‐bolism in the EINSTEIN DVT and EINSTEIN PE Studies
por: Prandoni, Paolo, et al.
Publicado: (2015)

Efficacy and safety of heparin plus dexamethasone after partial splenic embolization for liver cirrhosis with massive splenomegaly
por: Lu, Haohao, et al.
Publicado: (2022)

Rivaroxaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies
por: Wang, Yuqi, et al.
Publicado: (2013)

Cost-effectiveness analysis of treatment of venous thromboembolism with rivaroxaban compared with combined low molecular weight heparin/vitamin K antagonist
por: Bamber, Luke, et al.
Publicado: (2015)

The Pharmacology, Efficacy, and Safety of Rivaroxaban in Renally Impaired Patient Populations
por: Ashton, Veronica, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_a5hvlegl2s23n45s7t56ertq09